A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

被引：2

作者：

O'Donnell, Elizabeth K. ^{[1
]}

Mo, Clifton C. ^{[1
]}

Yee, Andrew J. ^{[2
]}

Nadeem, Omar ^{[1
]}

Branagan, Andrew R. ^{[3
]}

Laubach, Jacob ^{[4
]}

Rosenblatt, Jacalyn ^{[5
]}

Horick, Nora ^{[6
]}

Richardson, Paul G. ^{[7
]}

Raje, Noopur ^{[8
]}

Cirstea, Diana ^{[8
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA

[4] Harvard Med Sch, Dana Farber Partners CancerCare, Boston, MA 02115 USA

[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Dana Farber Canc Inst Inc, Boston, MA USA

[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1182/blood-2023-181019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4